CA-ALKIRA,-INC.
Network Cloud pioneer Alkira® today announced a close collaboration with the Microsoft for Startups program, a select group of emerging businesses hand-picked by Microsoft for the benefits they offer to Microsoft Azure customers in their journey to the cloud. The select start-ups receive growth partnership and ecosystem support from Microsoft including access to technical, sales and marketing opportunities and leadership. Alkira also announced that the Alkira Cloud Services Exchange (CSX) – the core of the company’s Network Cloud platform – is now available on the Azure Marketplace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005521/en/
The Alkira Network Cloud platform which reduces the time, cost and complexity of connectivity cloud environments, provides Azure customers with increased performance, manageability and security when deploying Windows workloads in the Azure cloud. Microsoft Azure customers can access Alkira’s solution in Azure, or in a multi-cloud network alongside other best-of-breed products in the Azure Marketplace.
Benefitting from the underlying power of Azure, Alkira CSX is delivered as a secure cloud networking infrastructure as-a-service that dynamically scales according to customers’ needs and reduces the time taken to deploy cloud networks from months to minutes.
Amir Khan, Chief Executive Officer and Founder of Alkira, said: “The time, cost and complexity of building networks in the cloud with end-to-end security and management visibility are major challenges holding back digital transformation. Our service was developed to help businesses overcome the trade-offs, complexity and long lead times associated with cloud networking. The Alkira Network Cloud platform accelerates the deployment and simplifies the management of cloud workloads, leaving customers free to focus on the objectives of their business. We’re excited to be deepening our relationship with Microsoft through the Microsoft for Startups program and to be able to offer those benefits to the growing number of organizations seeking transformational solutions from the Azure Marketplace.”
Jeff Ma, General Manager of Microsoft for Startups, commented: “Our start-up program gives new businesses access to the incredible resources of Microsoft and helps to bring the benefits of exciting new technologies like Alkira’s Network Cloud platform to Microsoft’s Azure customers. Alkira’s platform provides a powerful and flexible set of capabilities to leverage the power of Azure to deploy fully featured cloud networks.”
Mamoon Hamid, Partner at Kleiner Perkins added: “It’s time for the network to join the cloud era, and Alkira’s Cloud Networking Infrastructure as-a-Service provides customers a secure, simplified path to the Microsoft Azure cloud. Microsoft is progressively offering companies like Alkira the opportunity to help Azure customers on their cloud journey, and we're already seeing it unlock value for everyone involved."
Brad Casemore, Research Vice President, Datacenter Networks at IDC said: “IDC finds that enterprises are gaining greater appreciation of how modern infrastructure can support strategic cloud objectives such as business agility, application experience, robust security. That said, while enterprise architects want to help their organizations achieve greater business agility through the migration of workloads to cloud, they also want to ensure that the transition doesn’t entail compromises to operational control and management. Alkira’s Network Cloud platform addresses these requirements by helping organizations and their architects reconcile the business benefits of cloud with the need for effective control.”
Microsoft customers who access Alkira’s Network Cloud through Azure Marketplace benefit from reduced procurement overheads, simplified billing and quicker deployment, as well as the assurance of Microsoft certification.
For more information:
- Read Amir Khan’s blog on teaming with Microsoft
- Download an Alkira in Azure Cloud white paper
About Alkira
Alkira® developed the Network Cloud which enables Enterprises to build and deploy a global unified Cloud Network Infrastructure as-a-Service (CNaaS) that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira Cloud Services Exchange™ (CSX) seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of Integrated Solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.Alkira.com or follow us @AlkiraNet
Alkira® is a registered trademark and Alkira Cloud Services Exchange™ is a trademark of Alkira, Inc. All other marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005521/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom